¶ Glutamine
| Type | Amino Acid |
| Active Cmpd | L-Glutamine |
| Source | Endogenous synthesis; meat, dairy, eggs, beans |
| Dose Range | 5–30 g/day |
| Half-life | ~1 hour |
| Main Benefit | Intestinal barrier integrity & clinical recovery |
| Absorption | High (near 100%) |
L-Glutamine is the most abundant amino acid in the human body, acting as a critical metabolic fuel for immune cells and the intestinal lining. While well-supported for reducing intestinal permeability and aiding clinical recovery in critical illness or oncology protocols, robust human evidence does not support its use for muscle hypertrophy or athletic performance in healthy individuals.
¶ At a glance
Aliases
- Also known as: L-Glutamine, Gln, Q, 2-Aminoglutaramic acid
- Chemical / botanical name: (S)-2,5-Diamino-5-oxopentanoic acid
- Category: Amino acid (conditionally essential)
Key points (high-level summary)
- In adults with increased intestinal permeability, oral glutamine significantly reduces "leaky gut" markers by supporting enterocyte integrity.
- For patients in intensive care or with severe burns, glutamine supplementation reduces infectious complications and hospital length of stay.
- Despite heavy marketing in sports nutrition, glutamine fails to increase muscle mass, strength, or prevent post-exercise immunosuppression in healthy athletes.
- Use caution in cancer patients (unless part of a specific toxicity-reduction protocol) as some tumors are "glutamine-addicted" and use it for rapid growth.
What people use it for
- Main goals: Intestinal barrier support (leaky gut), recovery from surgery/trauma, reduction of chemotherapy/radiotherapy side effects, and muscle recovery.
- Evidence quality (overall): Moderate to High (clinical recovery/gut health); Low (sports performance).
¶ What is Glutamine?
L-Glutamine is a non-essential amino acid that becomes "conditionally essential" during periods of extreme physiological stress. Under normal conditions, the body synthesizes sufficient amounts in skeletal muscle and the lungs. However, during major trauma, surgery, or chronic illness, the demand from the immune system and gut mucosa can exceed the body's biosynthetic capacity, leading to systemic depletion.
- Definition: A proteogenic amino acid and the primary nitrogen carrier in the bloodstream.
- Natural sources: High-protein foods including beef, chicken, fish, dairy products, eggs, and plant sources like beans, cabbage, and spinach.
- Traditional / historical use: Historically used in clinical nutrition since the mid-20th century to manage hypermetabolic states and severe malnutrition.
- Current regulatory status: Generally Recognized as Safe (GRAS) in the US; widely available as a dietary supplement.
- Key pharmacological property: Primary metabolic substrate for rapidly dividing cells (enterocytes and lymphocytes).
¶ What are Glutamine’s main benefits?
Glutamine’s primary clinical value lies in its ability to maintain the structural integrity of the intestinal barrier and fuel the immune response during hypercatabolic states.
Intestinal Barrier Integrity
- Outcome: Reduction in intestinal permeability ("Leaky Gut").
- Direction of effect: Decrease.
- Magnitude: Moderate to Large.
- Population studied: Adults with increased permeability (e.g., post-infectious, exercise-induced, or clinical stress).
- Evidence quality: Moderate (Systematic reviews of RCTs).
- Summary sentence: Oral glutamine (up to 30g/day) significantly reduces the translocation of bacteria and endotoxins by supporting tight junction protein synthesis.
Clinical Recovery (ICU, Surgery, & Burns)
- Outcome: Hospital length of stay and infectious complications.
- Direction of effect: Decrease.
- Magnitude: Large.
- Population studied: Critically ill patients, post-operative surgical patients, and severe burn victims.
- Evidence quality: High (Multiple meta-analyses).
- Summary sentence: Supplements significantly shorten ICU stays and reduce the risk of secondary sepsis in severe trauma and burn patients.
Oncology Toxicity Mitigation
- Outcome: Severity of chemotherapy-induced diarrhea, oral mucositis, and radiodermatitis.
- Direction of effect: Decrease.
- Magnitude: Moderate.
- Population studied: Cancer patients undergoing chemotherapy or radiation.
- Evidence quality: Moderate (Mixed but leaning positive in meta-analyses).
- Summary sentence: Specific protocols utilizing oral glutamine can reduce the incidence of severe radiation-induced skin damage and mucositis.
¶ Evidence summary table (human outcomes)
| Outcome / Goal | Effect* | Consistency** | Evidence quality | Trials*** | Notes (population, duration, dose) |
|---|---|---|---|---|---|
| Intestinal Permeability | High | Moderate | 10+ RCTs | [Reduces L/M ratio; doses up to 30g/day for 2 weeks][1] | |
| ICU Length of Stay | High | High | 20+ RCTs | [Significantly reduces hospital stay in critically ill][2][3] | |
| Burn Recovery | High | High | 10+ RCTs | [Reduces mortality and sepsis in severe burn patients][4][5] | |
| Chemo-Induced Diarrhea | Moderate | Moderate | 8 RCTs | [Oral glutamine reduces severity in CRC patients][6] | |
| Radiodermatitis | High | Moderate | 5+ RCTs | [Significantly reduces radiation skin burn severity][7] | |
| Oral Mucositis | Moderate | Moderate | 15 RCTs | [Reduces duration/severity; results mixed in head/neck cancer][8][9] | |
| Muscle Hypertrophy | High | Low | 10+ RCTs | [No effect on muscle mass or strength in healthy athletes][10] | |
| Inflammation (CRP) | Moderate | Moderate | 12 RCTs | [Small to moderate reduction in serum CRP in chronic disease][11][12] |
- *Effect: Direction/Magnitude encoding (↑=increase, ↓=decrease, ==no effect, ?=unclear). (p)=positive, (n)=negative, (x)=neutral.
- **Consistency: Low (results conflict), Moderate (mixed), High (most trials agree).
- ***Trials: Number of RCTs informing the outcome.
- REQUIRED: See References section for corresponding meta-analyses and trials.
¶ How does Glutamine work?
Glutamine serves as a versatile metabolic hub, providing nitrogen for biosynthetic pathways and carbon for energy production.
- Primary targets: Enterocytes (intestinal cells), lymphocytes (immune cells), and skeletal muscle transporters (SNAT1/2).
- Core mechanisms:
- Enterocyte Metabolism: Glutamine is the preferred fuel for the intestinal mucosa. It is oxidized to provide ATP, maintaining the energy-intensive assembly of tight junction proteins like claudin-1 and occludin.
- Tight Junction Synthesis: By activating the mTOR and MAPK pathways, glutamine upregulates the expression of proteins that seal the gaps between intestinal cells, preventing "leaky gut" [13].
- Immune Proliferation: Lymphocytes and macrophages consume glutamine at rates similar to or higher than glucose. It provides the nitrogen required for nucleotide synthesis during rapid immune cell proliferation [2:1].
- Glutathione Precursor: Glutamine is converted to glutamate, a direct precursor for glutathione (GSH), the primary intracellular antioxidant.
- Pharmacokinetics:
- Absorption: Rapid and near-complete in the small intestine.
- Metabolic Splanchnic Extraction: Up to 70% of oral glutamine is consumed by the gut and liver before reaching systemic circulation, which explains why oral supplementation has limited effects on muscle tissues compared to the gut.
- Half-life: Approximately 1 hour in plasma.
Figure 1: Molecular role of L-glutamine in enterocyte metabolism and tight junction maintenance. Glutamine acts as a primary energy substrate for intestinal mucosal cells and fuels the expression of tight junction proteins (claudin, occludin), preventing paracellular bacterial translocation.
¶ Effects on different systems
¶ Gut & Digestion
The most robust application of glutamine is the maintenance of the intestinal barrier. In conditions of stress (strenuous exercise, infection, or surgery), the gut barrier often fails, allowing endotoxins to enter the blood. Glutamine supplementation (0.5g/kg body weight) has been shown to stabilize the barrier and prevent this translocation in numerous human trials [14][1:1]. In patients with IBD, clinical results remain mixed, with better evidence for barrier support than for reducing active disease inflammation [15].
¶ Clinical Recovery & Critical Illness
In the ICU, glutamine is considered a "conditionally essential" nutrient. Meta-analyses of dozens of RCTs show that either enteral or parenteral glutamine reduces hospital length of stay and infectious complications by roughly 20-30% in critically ill adults [2:2][3:1].
¶ Oncology Support
Glutamine is used off-label to manage the toxic side effects of cancer treatment. Meta-analyses confirm it reduces the severity of radiodermatitis [7:1], radiation enteritis [16], and chemotherapy-induced diarrhea [6:1]. It may also mitigate peripheral neuropathy [17], although evidence for oral mucositis is conflicting in head and neck cancers [9:1].